|
|
SENIOR MANAGEMENT
 Stephen T. Isaacs is Chairman, President and CEO of Aduro BioTech. Prior to Aduro, Mr. Isaacs was founder (1991), President and CEO of Cerus Corporation (NASD: CERS), a biomedical products company commercializing the Intercept Blood Systems. During his tenure at Cerus, Mr. Isaacs grew the company from three to over two hundred and fifty employees. He raised over $650M, negotiated a $200M partnership with Baxter International, took Cerus public and developed two marketed products. In 2002, while still at Cerus, Mr. Isaacs initiated the current Aduro BioTech immunotherapy program. The immunotherapy technology is based on attenuated strains of Listeria monocytogenes, and Mr. Isaacs was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Prior to Cerus, Mr. Isaacs was the CEO of a number of small biotech companies where he negotiated contracts and partnerships with Cetus Corporation, Chiron Corporation, Eastman Kodak, Hoffmann-La Roche and Applied Biosystems. He is an international expert in psoralen photochemistry, and from 1978 to 1986 held a non-teaching faculty position in the Department of Chemistry at UC Berkeley. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. He holds a BA degree in Biochemistry from UC Berkeley, and had graduate training in organic chemistry in the PhD program in the Department of Chemistry at Berkeley. He is also deeply involved in volunteer work in Kasigau, Kenya through his family non-profit organization, ABE Club, where his family has worked for the past 8 years.
 Seth David Model is acting CFO of Aduro. He came to Aduro from Triton BioSystems, one of the two companies that merged to form Aduro in 2008, where he was also CFO and a founder of the company. Mr. Model’s prior experience includes ImageMax, Inc., (now DataBank IMX), where he was a founder and President, and part of the group that took ImageMax public in 1997. Prior to that, Mr. Model co-managed Airfoil Technologies, LLC, a joint venture between Teleflex and General Electric to provide the world's commercial airlines with turbine repair services. (General Electric acquired 100% of the venture in 2009.)
Mr. Model began his career as a mechanical engineer with Pratt and Whitney Aircraft, designing engine components and later running development and test programs. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Yale University.
 Thomas Dubensky is Chief Scientific Officer of Aduro Biotech. He was a co-founder and Chief Scientific Officer of Anza Therapeutics, which was spun out from Cerus Corporation in 2007, where he served as the Vice President of Research beginning in 2002. At Cerus and at Anza he helped to develop vaccine platforms based on attenuated strains of Listeria monocytogenes, which serves as the technology basis for Aduro. Dr. Dubensky joined Aduro in 2011 from Immune Design Corporation, a biotechnology company that is developing immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms, where he served as Chief Scientific Officer. Previously, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA in positions of increasing responsibility at Viagene, Chiron and Onyx Pharmaceuticals. Several product candidates based on these platforms have been evaluated in human clinical trials in settings of infectious disease and cancer. Dr. Dubensky has co-authored more than 60 scientific papers and is an inventor on more than 25 issued U.S. patents and multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley; he earned his Ph.D. at the University of Colorado Health Sciences Center; and he was a post-doctoral fellow at Harvard Medical School in the Department of Pathology.
 Dirk G. Brockstedt is Senior Vice President of Research and Development, and has more than 15 years of experience in the fields of immunology and oncology originating with his PhD from Stanford University. He was the third employee in the original Vaccine group at Cerus Corporation and later brought the technology to Aduro. He was instrumental in the development of both the live-attenuated and killed Listeria strains, and he led the development of the lead product, CRS-207. Prior to Cerus Corporation, Dr. Brockstedt spent 4 years at Aventis in the Immunotherapy and Anti-Angiogenesis group developing novel therapies against cancer. Dr. Brockstedt is the author of more than 20 peer-reviewed scientific articles and is a named inventor on 5 issued patents and several patent applications.
 Aimee Murphy is the Director of Clinical Operations. She has more than 12 years of
experience in all phases of clinical research and trial management, with a
focus on therapeutic and prophylactic vaccines for cancer and infectious
diseases. While at Cerus
Corporation and Anza Therapeutics, she managed the first Phase 1 studies for
what are now Aduro's therapeutic vaccines. Prior to working with Aduro’s platform,
she worked at VaxGen for 6 years on the world's first Phase 3 prophylactic vaccine
trials for HIV-1 as well as vaccine trials for anthrax and smallpox. Prior to working in clinical
development, Ms. Murphy worked in Quality Assurance at Bayer Pharmaceuticals. She holds a BS in Biology from
Pepperdine University.
Justin is Director, Biodefense and Process Development, and has over 15
years of experience in microbiology. He has developed methods for the
GMP production of live-attenuated and KBMA Listeria vaccines. Dr.
Skoble earned his Ph.D. at University of California, Berkeley in the
laboratory of Dr. Daniel Portnoy investigating the interactions between Listeria monocytogenes and host cells. Dr. Skoble performed postdoctoral work at UCSF in the laboratory of Dr. Jeff Cox studying Mycobacterium tuberculosis pathogenesis.
|